Williams v. Ethicon, Inc. et al

Filing 141

MEMORANDUM OPINION AND ORDER (Motions in Limine) Plaintiff's 119 MOTION in Limine and Defendants' 122 OMNIBUS MOTION in Limine are GRANTED in part and DENIED without prejudice in part. The Plaintiff's Motion in Limine No. 1, t he Defendants' Motion in Limine No. 2, and any other conceded individual motion are GRANTED. All other Motions in Limine in ECF Nos. 119 and 122 are DENIED without prejudice, as more fully set forth herein. Signed by Judge Joseph R. Goodwin on 12/22/2016. (cc: counsel of record; any unrepresented party) (ts)

IN THE UNITED STATES DISTRICT COURT
FOR THE SOUTHERN DISTRICT OF WEST VIRGINIA
CHARLESTON DIVISION
NANCY WILLIAMS,
Plaintiff,
v.

CIVIL ACTION NO. 2:12-cv-511

ETHICON, INC., et al.,
Defendants.
MEMORANDUM OPINION AND ORDER
(Motions in Limine)
Pending before the court are the plaintiff’s Motion in Limine [ECF No. 119]
and the defendants’ Motion in Limine [ECF No. 122].
This case resides in one of seven MDLs assigned to me by the Judicial Panel
on Multidistrict Litigation concerning the use of transvaginal surgical mesh to treat
pelvic organ prolapse (“POP”) and stress urinary incontinence (“SUI”). In the seven
MDLs, there are more than 58,000 cases currently pending, approximately 28,000 of
which are in this MDL, which involves defendants Johnson & Johnson and Ethicon,
Inc. (collectively “Ethicon”), among others.
In this MDL, the court’s tasks include “resolv[ing] pretrial issues in a timely
and expeditious manner” and “resolv[ing] important evidentiary disputes.” Barbara
J. Rothstein & Catherine R. Borden, Fed. Judicial Ctr., Managing Multidistrict

Litigation in Products Liability Cases 3 (2011). The court seeks the assistance of the

parties in completing these tasks by asking the parties to focus on discrete, important,
or more relevant matters. Here, the court expected the parties to focus their motions
in limine on “highly prejudicial statements in opening or closing statements or
questions at trial that, once heard by the jury, cannot be easily cured by an instruction
to disregard.” Pretrial Order No. 234, at 5 [2:12-md-2327 ECF No. 2314] (“PTO 234”).
The court further cautioned that it would “not provide advisory opinions on the
admissibility of evidence a party may offer at trial and [would] summarily deny those
motions as premature.” Id.
a. The Plaintiff’s Motion to Preclude Evidence Relating to the FDA (Motion in
Limine No. 1) [ECF No. 119]
The plaintiff asks the court to exclude evidence related to the FDA, including
the FDA’s 510(k) process, arguing it is impermissibly irrelevant and prejudicial under
Federal Rules of Evidence 402 and 403. Pl.’s Mot. Lim. 1–4 [ECF No. 119].
In short, the 510(k) process “does not in any way denote official approval of [a]
device.” 21 C.F.R. § 807.97. The process is not focused on whether a device is safe; it
is concerned with the device’s equivalence to another device. Medtronic, Inc. v. Lohr,
518 U.S. 470, 493 (1996). Because the process does not speak to the safety or efficacy
of any product, whether Ethicon products were approved through this process is
irrelevant. Even if the 510(k) process were relevant, the court would exclude this
evidence under Rule 403. Any kernel of relevance is outweighed by “the very
substantial dangers of misleading the jury and confusing the issues.” In re C. R. Bard,
810 F.3d 913, 922 (4th Cir. 2016) (affirming the court’s exclusion of 510(k) evidence).
2

Put simply, evidence of this sort is inadmissible and, in any event, does not
survive a Rule 403 analysis. The court will not belabor the point here as it has already
done so on several occasions. E.g., Lewis v. Johnson & Johnson, 991 F. Supp. 2d 748,
754–56 (S.D. W. Va. 2014). The court GRANTS in part the plaintiff’s Motion in Limine
[ECF No. 119] as to Motion in Limine No. 1 and any other instance where the
defendants concede to the plaintiff’s Motion.
b. The Defendants’ Motion to Exclude the January 2012 “522” Letters and
Subsequent FDA Actions (Motion in Limine No. 2) [ECF No. 122]
The defendants ask the court to exclude evidence of the January 2012 “522”
letters and subsequent FDA actions that would have applied to Ethicon devices if
they had not been discontinued, arguing it is prejudicial and would require
presentation of evidence on a collateral issue. Defs.’ Mem. Supp. Mot. Lim. 3–6 [ECF
No. 123]. The plaintiff does not contest this Motion. Pl.’s Mem. Opp’n Defs.’ Mot. Lim.
4 [ECF No. 124]. Indeed, the court has excluded this same evidence on prior occasions.

See, e.g., Bellew v. Ethicon, Inc., No. 2:13-cv-22473, 2014 WL 6680356, at *1 (S.D. W.
Va. Nov. 25, 2014). The court GRANTS in part the defendants’ Motion in Limine [ECF
No. 122] on this point and any instance where the plaintiff concedes to the defendants’
Motion.
c. Remaining Motions in ECF Nos. 119, 122
The remaining individual motions do not comport with PTO 234’s requirement
to focus on “highly prejudicial statements in opening or closing statements or
questions at trial that, once heard by the jury, cannot be easily cured by an instruction

3

to disregard” and are more appropriately handled by the trial court judge following
remand or transfer at or before trial. PTO 234 at 5. Accordingly, the plaintiff’s Motion
in Limine [ECF No. 119] and the defendants’ Motion in Limine [ECF No. 122] are
GRANTED in part and DENIED without prejudice in part. The plaintiff’s Motion in
Limine No. 1, the defendants’ Motion in Limine No. 2, and any other conceded
individual motion are GRANTED. All other Motions in Limine in ECF Nos. 119 and
122 are DENIED without prejudice.
The court DIRECTS the Clerk to send a copy of this Order to counsel of record
and any unrepresented party.
ENTER:

4

December 22, 2016